In the Med. Chem. department, we apply cutting-edge medicinal chemistry to design and synthesise potential patentable bioactive molecules that afford safe target engagement to address unmet patient needs. In fewer words:

And we do so in multi-disciplinary and collaborative project teams by using our expertise in targeting brain diseases.

This first year at Lundbeck has been exciting and productive thanks to a steep learning curve, and with the promise of more to come. Here I have found a working environment built to thrive on excellence, ambition, creativity and collaboration. I trust this as a strong base to succeed the challenging science outcomes needed to improve the treatments for patients living with brain diseases.

I see myself having further led some of the now early activity projects close to (or into!) clinical development, and I see Lundbeck having filled up our late-stage pipeline with compounds developed in-house. The recent expansion of our operating space has opened exciting possibilities to target a broader range of brain diseases. With the firm aim of restoring brain health, novel upcoming projects are in need of innovative molecules to be developed in-house by using our high expertise, skills and capabilities, and I expect that to be reflected in the upcoming years by a well-populated, top-quality pipeline over all clinical and pre-clinical phases.

Enjoying the Copenhagen summer. This might sound ironic, because summer here can be very short to non-existent, but the moment spring has sprung -which can be as late as June, the city opens completely to long light days, comfortable summer heat, numerous street festivals, multicultural events happening in the very distinct yet equally captivating neighbourhoods and endless outdoor opportunities. Biking in a swimsuit around the city’s canals and the transition of bike-to-swim on a hot sunny day is the definite pinnacle of life in Copenhagen.